Importance of Measuring Serum C-peptide in the Biological Care of Hyperglycemia Patients and Diabetics’ Patients on Insulin in Côte d’Ivoire

Lydie Boyvin^{1, 2,} , Zazou Ange Kevin Zokoré², Aya Jeanne Armande Aké², Yao Nestor N’Guessan², Kipré Laurent Séri², Adou Francis Yapo² and Allico Joseph Djaman^{1, 2}

¹Department of Fundamental & Medical Biochemistry, Institut Pasteur of Cote d'Ivoire (IPCI), 01 BP 490 Abidjan 01 (Côte D’Ivoire)

²Pharmacodynamie- Biochemical Laboratory, University Félix Houphouët-Boigny of Abidjan (UFHB), 22 BP 582 Abidjan 22 (Côte d’Ivoire)

Cite this paper:
Lydie Boyvin, Zazou Ange Kevin Zokoré, Aya Jeanne Armande Aké, Yao Nestor N’Guessan, Kipré Laurent Séri, Adou Francis Yapo and Allico Joseph Djaman. Importance of Measuring Serum C-peptide in the Biological Care of Hyperglycemia Patients and Diabetics’ Patients on Insulin in Côte d’Ivoire. American Journal of Medical and Biological Research. 2018; 6(1):16-20. doi: 10.12691/ajmbr-6-1-4

Abstract

Diabetes, the leading cause of high blood glucose, is a pandemic disease with serious complications (paralyzing, deadly) despite the available diabetes treatment. C -Peptide, is generally secreted in amounts equal to insulin in the blood, is a reliable marker of insulin function and production in diabetics patients under insulin therapy. In Côte d’Ivoire, the prevalence of diabetes is 2.3% (2015) and no study has been conducted so far on the C-peptide to evaluate the actual proportion of insulin in high blood glucose. This is a prospective study based on cases-controls conducted on a cohort of 60 patients and 30 controls from the period of November 2015 to February 2016 .The study involved only adult patients’ with hyperglycemia blood samples on one hand and those assumed diabetics on insulin therapy. Pregnant women and children were not included. Analysis of C-peptide was performed on the sera from blood samples collected. Using ELISA kit chain PR 4100 by Bio-rad. The results show that the mean value of the C- peptide is normal with no significant difference in patients with hyperglycemia (P = 0.1343). However, the difference is significant in diabetics patients on insulin therapy (p < 0.0001). In conclusion, the determination of C-peptide level allowed knowing the amount of insulin secreted by the pancreas. It would be better, with the persistence situation of hyperglycemia, to evaluate the concentration level of C-peptide before commencement of any diabetes treatment exogenous insulin in particular.

Keywords:
Côte d’Ivoire C-peptide Diabetes Hyperglycemia Insulin

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	WHO. Global report on diabetes. 2016. Geneve. WHO_NMH_NVI_16.3_
[2]	Hirst M. Atlas du diabète, 2013. USA. Sixième édition, ISBN. 160 p.
[3]	WHO/IDF. International Diabetes Federation (IDF). Annual Report 2014. Resources/2015-atlas WHO/IDF (International Diabetes Federation). 2015. 144 p.
[4]	Geoffroy L, Gonthier M. L’hyperglycémie et l’acidose diabétique. In Le diabète chez l’enfant et l’adolescent. Montréal, 2éd. Éditions du CHU Ste-Justine. 2012; 355-364.
[5]	Grimaldi A, Bosquet F, Halbron M, Hartemann-Heurtier A, Jacqueminet S, Masseboeuf N, Sachon C. Guide pratique du diabète. 2005. Paris. ed Masson, Elsevier 271 p.
[6]	Vasic, D. & Walcher, D. Proinflammatory Effects of C-Peptide in Different Tissues. International Journal of Inflammation, ID 932725: 1-7.2012.
[7]	Vezzosi, D., Bennet, A., Fauvel, J., Caron, P. Insulin, C-peptide and proinsulin for the biochemical diagnosis of hypoglycaemia related to endogenous hyperinsulinism. European Journal of Endocrinology, 157(5):693. Nov 2007.
[8]	Akuri, R.S., Suleman, D. Role of c-peptide and c-peptide glucose ratio in assessing decreased beta cell function in chronic pancreatic disorders. World Journal of Pharmacy and Pharmaceutical Sciences, 3(8): 2156-2163. 2014.
[9]	Zhang, J. & Liu, F. Tissue-specific Insulin Signaling in the Regulation of Metabolism and Aging. International Union of Biochemistry and Molecular Biology Life, 66: 485-495. 2014.
[10]	Deyhimi, F., Arabie, M., Parvin L. Optimization of the Emerson–Trinder enzymatic reaction by response surface methodology. Biocatalysis and Biotransformation, 24: 263-271. 2006.
[11]	Gaillard, O. Le peptide C. Immuno-analyse & Biologie Spécialisée, 15: 94-95. 2000.
[12]	Jones G A, Hattersley T A. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabetic Medicine, 30: 803-817. 2013.
[13]	Martín-Timón, I., Sevillano-Collantes,C., Segura-Galindo, A., del Cañizo-Gómez, FJ. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World Journal of Diabetes, 5(4):444-470. 2014
[14]	Schnell, O., Cappuccio, F., Genovese, S., Standl, E., Valensi, P. et al. Type 1 diabetes and cardiovascular disease. Cardiovascular Diabetology, 12: 156. 2013.
[15]	Boyda, H.N., Procyshyn, R.M., Tse, L., Hawkes, E., Jin, C.H., Pang, C.C., Honer, W.G., Barr, A.M. Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. Journal of Psychiatry & Neuroscience, 37: 407- 415. 2012.
[16]	Sayed M H, Hegazi M A, Abdulwahed K, Moussa K, El-Deek B S et al. Risk factors and predictors of uncontrolled hyperglycemia and diabetic ketoacidosis in type 1 diabetic children and adolescents, in Jeddah, Western Saudi Arabia. Journal of Diabetes, 2016.
[17]	Umpierrez G E, Isaacs S D, Bazargan N, You X, Thaler L M, Kitabchi A E. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. Journal of clinical endocrinology and metabolism, 87: 978-982. 2002.